The stock of clinical contract research organization Medpace (Nasdaq: MEDP) is taking a hit today after the company’s CEO Dr. August Troendle told analysts that the company is facing a “relatively permanent or increasing margin headwind in the next few years.”
Medpace’s stock is down about 16%, trading around $33 per share, in morning trading. Troendle in a conference call with analysts this morning said he expected the company’s EBITDA margin — its earnings before interest, taxes, depreciation and amortization as a percentage of total revenue — to be 25% in 2018, down from 28% in 2017.
Get the full story on our sister site Medical Design & Outsourcing.
The post Medpace stock down after CEO talks of ‘permanent or increasing margin headwind’ appeared first on MassDevice.
from MassDevice http://ift.tt/2CpyIyU
Cap comentari:
Publica un comentari a l'entrada